Topiramate and Ubrelvy (Ubrogepant) Can Be Used Together Safely
There is no clinically significant drug interaction between topiramate and ubrogepant (Ubrelvy), and these medications can be safely coadministered for migraine management 1.
Pharmacokinetic Interaction Profile
When topiramate and ubrogepant are taken together, there is a modest 25% reduction in ubrogepant exposure (both AUC and Cmax decreased by approximately 24-25%) 1. However, this reduction is not considered clinically relevant and does not require dose adjustments 1.
The interaction works in only one direction:
- Topiramate reduces ubrogepant levels by 25% (topiramate acts as a weak CYP3A4 inducer)
- Ubrogepant has minimal effect on topiramate levels (only 5-6% reduction in topiramate exposure) 1
Clinical Implications
The 25% reduction in ubrogepant exposure when combined with topiramate falls well within the acceptable range for clinical use. This is particularly reassuring because:
- The FDA label for ubrogepant 2 contraindicates strong CYP3A4 inhibitors but only recommends avoiding strong CYP3A4 inducers
- Topiramate is a weak inducer, not a strong one
- The modest reduction in ubrogepant levels does not compromise its therapeutic efficacy for acute migraine treatment
Practical Prescribing Approach
Continue both medications at standard doses:
- Topiramate: Continue at the prescribed preventive dose (typically 25-200 mg daily for migraine prevention) 3
- Ubrogepant: Use standard acute dosing of 50 mg or 100 mg as needed, with a second dose possible after 2 hours if needed (maximum 200 mg per 24 hours) 2
Safety Considerations
This combination is well-tolerated with no new safety signals identified 1. The most common adverse reactions with ubrogepant alone are nausea and somnolence 2, and these are not increased when combined with topiramate.
Important monitoring points:
- Watch for new-onset or worsening hypertension (ubrogepant warning) 2
- Monitor for new-onset or worsening Raynaud's phenomenon (ubrogepant warning) 2
- Be aware of medication overuse headache risk if ubrogepant is used ≥10 days per month 4
Guideline Context
The 2025 ACP guidelines 4 position gepants like ubrogepant as options for acute migraine treatment when patients have inadequate response to or cannot tolerate triptan plus NSAID combination therapy. Using ubrogepant for acute treatment while on topiramate for prevention aligns with evidence-based migraine management, as preventive medications are warranted when episodic migraines occur frequently or acute treatment provides inadequate response 4.